Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report

BACKGROUND: Direct antiviral agent (DAA) has been the standard of care for patients with hepatitis C virus (HCV) infection. Twelve weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir (PROD) with or without ribavirin has shown to have a sustained virological response at post-treatment 12 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chung-Feng, Jang, Tyng-Yuan, Lu, Po-Liang, Yu, Ming-Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134859/
https://www.ncbi.nlm.nih.gov/pubmed/27893666
http://dx.doi.org/10.1097/MD.0000000000005304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134859/
https://www.ncbi.nlm.nih.gov/pubmed/27893666
http://dx.doi.org/10.1097/MD.0000000000005304

Ejemplares similares